» Articles » PMID: 38438800

Lipid Metabolism and Its Implications in Tumor Cell Plasticity and Drug Resistance: What We Learned Thus Far?

Overview
Specialty Oncology
Date 2024 Mar 4
PMID 38438800
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic reprogramming, a hallmark of cancer, allows cancer cells to adapt to their specific energy needs. The Warburg effect benefits cancer cells in both hypoxic and normoxic conditions and is a well-studied reprogramming of metabolism in cancer. Interestingly, the alteration of other metabolic pathways, especially lipid metabolism has also grabbed the attention of scientists worldwide. Lipids, primarily consisting of fatty acids, phospholipids and cholesterol, play essential roles as structural component of cell membrane, signalling molecule and energy reserves. This reprogramming primarily involves aberrations in the uptake, synthesis and breakdown of lipids, thereby contributing to the survival, proliferation, invasion, migration and metastasis of cancer cells. The development of resistance to the existing treatment modalities poses a major challenge in the field of cancer therapy. Also, the plasticity of tumor cells was reported to be a contributing factor for the development of resistance. A number of studies implicated that dysregulated lipid metabolism contributes to tumor cell plasticity and associated drug resistance. Therefore, it is important to understand the intricate reprogramming of lipid metabolism in cancer cells. In this review, we mainly focused on the implication of disturbed lipid metabolic events on inducing tumor cell plasticity-mediated drug resistance. In addition, we also discussed the concept of lipid peroxidation and its crucial role in phenotypic switching and resistance to ferroptosis in cancer cells. Elucidating the relationship between lipid metabolism, tumor cell plasticity and emergence of resistance will open new opportunities to develop innovative strategies and combinatorial approaches for the treatment of cancer.

Citing Articles

Carnitine O-Acetyltransferase as a Central Player in Lipid and Branched-Chain Amino Acid Metabolism, Epigenetics, Cell Plasticity, and Organelle Function.

Volpicella M, Sgobba M, Laera L, Francavilla A, De Luca D, Guerra L Biomolecules. 2025; 15(2).

PMID: 40001519 PMC: 11852590. DOI: 10.3390/biom15020216.


Identification of Lipid Species Signatures in FOLFOXIRI-Resistant Colorectal Cancer Cells.

Ramzy G, Meister I, Rudaz S, Boccard J, Nowak-Sliwinska P Int J Mol Sci. 2025; 26(3).

PMID: 39940937 PMC: 11818583. DOI: 10.3390/ijms26031169.


Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity.

Cioce M, Arbitrio M, Polera N, Altomare E, Rizzuto A, De Marco C Cancer Drug Resist. 2024; 7:45.

PMID: 39624081 PMC: 11609178. DOI: 10.20517/cdr.2024.131.


Biomarkers of systemic treatment response: MR images of intratumoral fat deposition in colorectal liver metastases (CRLM) after chemotherapy.

Morawska I, Pasicz K, Cieszanowski A Int J Colorectal Dis. 2024; 39(1):185.

PMID: 39562379 PMC: 11576797. DOI: 10.1007/s00384-024-04762-0.


Prognostic Prediction and Immune Microenvironment Characterization in Uveal Melanoma: A Novel Mitochondrial Metabolism-Related Gene Signature.

Cai W, Chen R, Liu Z, Lai J, Hou L, Zhang R ACS Omega. 2024; 9(42):43034-43045.

PMID: 39464480 PMC: 11500162. DOI: 10.1021/acsomega.4c06294.


References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Graham T, Sottoriva A . Measuring cancer evolution from the genome. J Pathol. 2016; 241(2):183-191. DOI: 10.1002/path.4821. View

3.
Hanahan D . Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1):31-46. DOI: 10.1158/2159-8290.CD-21-1059. View

4.
You M, Xie Z, Zhang N, Zhang Y, Xiao D, Liu S . Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023; 8(1):196. PMC: 10172373. DOI: 10.1038/s41392-023-01442-3. View

5.
Juliano R . Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides. NAR Cancer. 2020; 2(3):zcaa025. PMC: 7520847. DOI: 10.1093/narcan/zcaa025. View